SPC-14 shows cognitive and stress reduction benefits in preclinical models SARASOTA, FL, April 10, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has exercised its option to license Alzheimer’s... Read More

Exclusive license for development, manufacturing, and commercialization in process Silo Pharma to file Pre-IND in first half 2024 SARASOTA, FL, March 20, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced... Read More

Silo reports positive stability of SP-26 for time-release and dosage control SARASOTA, FL, March 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has filed a provisional patent application... Read More

All animal subjects tolerated maximum dosing Once-per-day human intranasal dosing regimen determined for clinical evaluation SARASOTA, FL, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced... Read More

Initial indications target fibromyalgia and chronic pain Loaded and encapsulated drug maintains structural stability as implantable treatment SARASOTA, FL, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today... Read More

Preparing Pre-Investigational New Drug Application for lead drug program SPC-15 Company plans to pursue FDA streamlined 505(b)(2) pathway for clinical drug development SARASOTA, FL, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. ( Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and... Read More

Preclinical study shows SPC-14’s effectiveness against LH (luteinizing hormone) stress, helplessness, and anxiety. SARASOTA, FL, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a biopharmaceutical company developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that its Alzheimer’s disease therapeutic SPC-14... Read More

Final validation report expected in first quarter 2024 ENGLEWOOD CLIFFS, NJ, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today provided an update on its previously announced dose-ranging study of SPC-15, a targeted prophylactic treatment for post-traumatic... Read More

Silo dosage and time-release formulation aim for potential first at-home Ketamine therapeutic SARASOTA, FL, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced an update on its dosage and time-release ketamine-loaded implant, designated as SP-26,... Read More

MedSpray’s patented nose-to-brain intranasal technology selected for SPC-15 drug delivery Exclusivity covers multiple indications including anxiety disorders, Alzheimer’s disease, and anorexia ENGLEWOOD CLIFFS, NJ, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research,... Read More

ENGLEWOOD CLIFFS, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a dose-ranging study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (PTSD). The study will identify the maximum... Read More

Human tissue study assessed SPU-21’s efficiency, optimization, and binding affinity ENGLEWOOD CLIFFS, NJ, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced positive data from a preclinical study investigating the binding affinity and optimization of SPU-21... Read More

Study to test effectiveness of Instructional System Designs (ISD) model for Intranasal SPC-15 ENGLEWOOD CLIFFS, NJ, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a human factor study of its targeted prophylactic treatment SPC-15 for the... Read More

Pre-IND submission to FDA targeted for first quarter 2024 Silo partners with Kymanox for SPC-15 ENGLEWOOD CLIFFS, NJ, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that based on positive SPC-15 pre-clinical data, it is working with Kymanox as its... Read More

Investigational New Drug (IND) submission to FDA on target for Q1 2024 SPC-15, is a novel Serotonin 4 receptor agonist against stress, developed in conjunction with Columbia University ENGLEWOOD CLIFFS, NJ, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced... Read More

Clarivate will monitor, manage, and maintain Company’s expanding IP portfolio ENGLEWOOD CLIFFS, NJ, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, announced today that it has retained the services of Clarivate™ , a leading global provider of information services including... Read More

Study data to determine potential delivery partners ENGLEWOOD CLIFFS, NJ, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has advanced the formulation development for its therapeutic drug, SPC-15. The liquid nasal formulation will be used in... Read More

ENGLEWOOD CLIFFS, NJ / ACCESSWIRE / June 23, 2023 / This month, Silo Pharma (NASDAQ:SILO) announced a new research and development agreement to create a time-release ketamine implant to treat fibromyalgia and other chronic pain conditions. The development-stage biopharma company has a portfolio of therapies in its pipeline that merge traditional therapeutics with the latest psychedelic research in its pipeline. Silo is... Read More

ENGLEWOOD CLIFFS, NJ, June 21, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 16/825,371 titled “Peptide-Targeted Liposomal Delivery for Treatment, Diagnosis, and Imaging of Diseases and... Read More

Initial indications are fibromyalgia and chronic pain ENGLEWOOD CLIFFS, NJ, June 13, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced its entry into a research and development agreement to study and develop a dosage and time-release ketamine implant for the treatment... Read More

Webull’s investor community can now access the SILO profile for real-time data and investor communications ENGLEWOOD CLIFFS, NJ, June 02, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it is now actively participating on the Webull Corporate Communications... Read More

Phase 2 of study will further investigate the peptides’ method, optimization, and binding affinity in human tissue ENGLEWOOD CLIFFS, NJ, May 30, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced its entry into a research agreement expanding the study of its novel... Read More

ENGLEWOOD CLIFFS, NJ, May 09, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 11,622,948 titled “Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders.”... Read More

ENGLEWOOD CLIFFS, NJ, April 24, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that James Kuo, M.D., Vice President of R&D, will speak at the 3rd Annual Psychedelic Therapeutics and Drug Development Conference being held May 15-16, 2023, in person, at the Hilton... Read More

ENGLEWOOD CLIFFS, NJ, April 19, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has commenced development of a novel formulation as a targeted prophylactic treatment, designated as SPC-15, intended for stress, anxiety, and PTSD. Development of the drug... Read More

SPU-26 Pain Management Using Ketamine Composition Action supports planned IND package submission to FDA for SP-26 ENGLEWOOD CLIFFS, NJ, March 27, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (the “Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has filed a provisional patent application titled “Methods and... Read More

ENGLEWOOD CLIFFS, NJ, March 15, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has achieved positive results for its toxicology study of SP-26, its novel time-released, dosage-controlled formulation of ketamine. The study results evaluated the feasibility... Read More

Patent application covers use of novel homing peptides to reduce toxicity and advance payload of therapeutic ENGLEWOOD CLIFFS, NJ, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has filed a provisional patent application for the use of its central... Read More

ENGLEWOOD CLIFFS, NJ, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (USPTO) today issued U.S. Patent 11,491,120, titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders In Females.” The... Read More

ENGLEWOOD CLIFFS, NJ, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its board of directors has authorized a share repurchase program to acquire up to $1,000,000 of the Company's common stock. The Company may purchase common stock in the open market,... Read More

Parkinson's disease, bipolar disorder, and chronic pain targeted in study Study aims to support psilocybin as a potential therapeutic for inflammatory disorders ENGLEWOOD CLIFFS, NJ, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced a progress update on its... Read More

SPU-21 effective in controlling arthritis progression. SPU-21 Demonstrates Positive Data in Arthritis Suppression using Silo’s Novel Joint Homing Peptide ENGLEWOOD CLIFFS, NJ, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced positive interim data from its... Read More